Neurocrine Survey Reveals Tardive Dyskinesia's Severe Workplace Impact

Event summary

  • 1 in 5 working adults with tardive dyskinesia (TD) quit jobs due to untreated symptoms
  • TD patients missed an average of 8 hours of work/school weekly pre-treatment
  • Survey of 100 individuals (70 TD patients, 30 caregivers) conducted Jan-Feb 2026
  • Only 10% of TD patients receive VMAT2 inhibitor treatment despite clinical guidelines
  • 60% of estimated 800,000 U.S. TD patients remain undiagnosed

The big picture

Neurocrine's survey highlights the severe workplace disruption caused by untreated TD, reinforcing the need for earlier diagnosis and treatment adherence. The data comes as Neurocrine seeks to expand its market for VMAT2 inhibitors in a space where clinical guidelines remain underutilized. The findings may bolster Neurocrine's advocacy efforts during Tardive Dyskinesia Awareness Week, potentially influencing both patient behavior and payer coverage policies.

What we're watching

Diagnostic Lag
Whether Neurocrine can accelerate TD diagnosis rates through awareness campaigns
Treatment Uptake
How Neurocrine will address the 90% untreated TD patient gap
Market Expansion
The pace at which Neurocrine can convert undiagnosed patients to treated cases